Drug Trial Radar · NCT07629817
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,044
Planned (sponsor's estimate)
Start
Jun 16, 2026
Primary completion
Mar 15, 2032
Study completion Mar 15, 2032
Sponsor
- Lead sponsor
- Henan Cancer HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Jun 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, multicenter, open-label, randomized controlled trial. The study aims to compare organ preservation versus esophagectomy in patients with locally advanced, resectable thoracic esophageal squamous cell carcinoma (ESCC) who achieve a complete or partial clinical response (cCR/cPR) following neoadjuvant immunochemotherapy.
Conditions
- Esophageal Squamous Cell Carcinoma
Interventions
Toripalimab + Nab-paclitaxel + Platinum-based ChemotherapyDrug
This is the standard induction therapy administered to all enrolled patients. It consists of the PD-1 inhibitor Toripalimab combined with Nab-paclitaxel
Radiation with Concurrent ChemotherapyCombination product
Chemotherapy administered concurrently with radiotherapy
Radical EsophagectomyProcedure
Standard surgical procedure with lymph node dissection
Primary outcomes
What the sponsor says the trial is designed to measure.
- 3-year Event-Free Survival (EFS) RateTime frame: 3 years after randomization/treatment initiation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.